Osaka University

Kobe University

Yoshiko Hashii

Toshiro Shirakawa

Takane Katayama

Keiichi Ozono

It is an object to provide a combination therapy effective in cancer immunotherapy. The object is achieved by providing an anti-tumor agent, including a transformedcontaining DNA encoding a WT1 protein and DNA encoding a GNB/LNB substrate-binding membrane protein derived from a, the transformedbeing designed to display the WT1 protein as an antigen on a surface of the transformed, the anti-tumor agent being for use in combination with an immunosuppression inhibitor. The transformedcan be used as an oral tumor vaccine.

Cancer therapy utilizing combination of oral tumor vaccine and immunosuppression inhibitor

A cancer vaccine that can be orally administered can be provided through the use of a transformedcapable of expressing and displaying a WT1 protein. The WT1 protein expressed and displayed by the transformedis a protein covering most of a WT1 protein unlike a WT1 peptide vaccine restricted to a certain HLA. A cancer vaccine using the transformedas an active ingredient is applicable to patients of various HLA types.

Growing community of inventors

Osaka, Japan

Yoshiko Hashii